Search Results - "Aglione, S."

167P PEMETREXED IN MESOTHELIOMA: POLONORD GROUP EXPERIENCE by Bertolini, A, Fagnani, D, Ardizzoia, A, Menatti, E, Aglione, S, Filipazzi, V, Isa, L, Donghi, M, Pona, C. Della, Robustellini, M

Get full text

Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer by Bajetta, E., Stani, S. C., De Candis, D., Zaffaroni, N., Zilembo, N., Cortinovis, D., Aglione, S., Mariani, L., Formisano, B., Bidoli, P.

“…Background: To explore the activity and tolerability of gemcitabine (GEM) and carboplatin (CBDCA) in non-small-cell lung cancer (NSCLC) we tested four…”
Get full text

9085 A platinum based second line rechallenge chemotherapy improves survival in small cell lung cancer patients by Laverde, N, Torri, V, Lo Dico, M, Galetta, D, Martelli, O, Michetti, G, Aglione, S, Sburlati, P, Fatigoni, S, Farina, G

Get full text

Metastatic melanoma: Chemotherapy by Bajetta, Emilio, Del Vecchio, Michele, Bernard-Marty, Chantal, Vitali, Milena, Buzzoni, Roberto, Rixe, Olivier, Nova, Paola, Aglione, Stefania, Taillibert, Sophie, Khayat, David

“…The incidence of cutaneous melanoma has been rapidly increasing, with an estimate of 47,700 new cases diagnosed in 2000 in the United States. In the early…”
Get full text

Outcomes of small cell lung cancer (SCLC) patients treated with second-line chemotherapy (SL): A retrospective analysis of 166 patients by Garassino, M. C., Michetti, G., Lo Dico, M., Califano, R., Aglione, S., Borgonovo, K., Mancuso, A., Galetta, D., Gallerani, E., Collovà, E., Torri, V.

“…Abstract only e19093 Background: Patients with SCLC progressed after first-line chemotherapy (FL) have a poor prognosis and the evidence of a benefit of SL is…”
Get full text

The efficacy of second line chemotherapy (CHT) in platinum-sensitive advanced/metastatic small cell lung cancer (SCLC) patients: Results of an ongoing Italian multicenter survey by Martelli, O., Cinquini, M., Mancuso, A., Borgonovo, K., Petrelli, F., Sergi, C., Paleari, D., Fatigoni, S., Sdrobolini, A., Aglione, S.

“…Abstract only 18090 Background: Despite CHT and radiotherapy for SCLC, most patients (pts) die within 2 years. Response rates for second-line CHT are low, with…”
Get full text

Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer by Bidoli, Paolo, Stani, Simonetta C, Mariani, Luigi, Candis, Daniela De, Cortinovis, Diego, Aglione, Stefania, Zilembo, Nicoletta, Toffolatti, Luisa, Formisano, Barbara, Bajetta, Emilio

“…Purpose: Oxaliplatin (OHP) is a new platinum antineoplastic, while gemcitabine (GEM) is one of the most active drugs against non-small cell carcinoma (NSCLC)…”
Get full text

Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IVnon-small-cell lung cancer by Bajetta, E., Stani, S.C., De Candis, D., Zaffaroni, N., Zilembo, N., Cortinovis, D., Aglione, S., Mariani, L., Formisano, B., Bidoli, P.

Get full text

New strategies in the treatment of esophageal cancer by Bidoli, P, Aglione, S, Toffolatti, L, De Candis, D, Bajetta, E

“…Esophageal cancer is uncommon, but its incidence is rapidly increasing in the Western countries because of the high incidence of the cardia esophageal…”
Get more information